These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11381568)

  • 21. Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis.
    Zintzaras E; Bouka P
    Eur J Drug Metab Pharmacokinet; 1999; 24(3):225-32. PubMed ID: 10716060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
    Molins E; Cobo E; Ocaña J
    Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modifications of sequential designs in bioequivalence trials.
    Zheng C; Zhao L; Wang J
    Pharm Stat; 2015; 14(3):180-8. PubMed ID: 25663282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample sizes for clinical trials with normal data.
    Julious SA
    Stat Med; 2004 Jun; 23(12):1921-86. PubMed ID: 15195324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies.
    Hauschke D; Steinijans WV; Diletti E; Schall R; Luus HG; Elze M; Blume H
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):376-8. PubMed ID: 7952801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical guide to sample size calculations: non-inferiority and equivalence trials.
    Flight L; Julious SA
    Pharm Stat; 2016; 15(1):80-9. PubMed ID: 26604186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exact sample-size determination in testing non-inferiority under a simple crossover trial.
    Lui KJ; Chang KC
    Pharm Stat; 2012; 11(2):129-34. PubMed ID: 22232060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary model to avoid the overestimation of sample size in bioequivalence studies.
    Ramírez E; Abraira V; Guerra P; Borobia AM; Duque B; López JL; Mosquera B; Lubomirov R; Carcas AJ; Frías J
    Drug Res (Stuttg); 2013 Feb; 63(2):98-103. PubMed ID: 23427051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency estimator for assessing of follow-on biologics.
    Lu Y; Zhang ZZ; Chow SC
    J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
    Nguyen TT; Bazzoli C; Mentré F
    Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equivalence testing with dental clinical trials.
    Burns DR; Elswick RK
    J Dent Res; 2001 Jun; 80(6):1513-7. PubMed ID: 11499504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A note on sample size calculation in bioequivalence trials.
    Hauschke D
    J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):89-94; author reply 99. PubMed ID: 12194537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
    Knahl SIE; Lang B; Fleischer F; Kieser M
    Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence trials with the incomplete 3 x 3 crossover design.
    Lim NK; Park SG; Stanek E
    Biom J; 2005 Oct; 47(5):635-43. PubMed ID: 16385904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.